Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium
NCT05343572
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This study will assess the use of autologous bone marrow stem cells mobilization using 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane (PLERIXAFOR) as an effective medical therapy for the treatment of Asherman's Syndrome (AS), Atrophic Endometrium (AE) and Recurrent Implantation Failure (RIF).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Asherman Syndrome
- Atrophic Endometrium
- Recurrent Implantation Failure
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Early Phase 1
- Ages
- 18 to 40 years
- Sex
- Female
- Healthy volunteers
- Accepted
- Sponsor
- Hugh Taylor
- Last updated on ClinicalTrials.gov
- November 12, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Connecticut · 1
- Yale Fertility Center · Orange, CT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.